Stock Markets June 24, 2026 12:05 PM

Belgian equities slip as BEL 20 closes down 0.72%

Healthcare, basic materials and utilities weigh on Brussels benchmark amid mixed commodity and FX moves

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
ABI ARGX

Belgian stocks retreated at Wednesday's close, with the BEL 20 index finishing 0.72% lower. Losses were concentrated in the Healthcare, Basic Materials and Utilities sectors. Several large-cap names bucked the trend to finish higher, while notable declines in individual stocks drove much of the downside. Commodities and currency measures also moved lower or were mixed at the close.

Belgian equities slip as BEL 20 closes down 0.72%
ABI ARGX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Belgium's BEL 20 index closed down 0.72%, with weakness concentrated in Healthcare, Basic Materials and Utilities.
  • Top winners included Montea (MONTE), Azelis (AZE) and Anheuser Busch Inbev (ABI); largest losers were Argen-X (ARGX), Umicore (UMI) and Aperam (APAM).
  • Commodities retreated: August gold, August crude and September Brent all fell; the US Dollar Index edged higher while major EUR pairs were largely unchanged.

Belgian equities ended Wednesday's session in negative territory as sector pressure from Healthcare, Basic Materials and Utilities pushed the benchmark lower.

At the close in Brussels, the BEL 20 index fell 0.72%.


Top performers on the BEL 20

  • Montea C.V.A. (EBR:MONTE) led gains on the index, rising 3.70% - a 2.40 point increase - to finish at 67.30.
  • Azelis Corporate Services NV (EBR:AZE) advanced 3.60%, up 0.35 points to close at 9.93.
  • Anheuser Busch Inbev SA NV (EBR:ABI) also posted a positive close, trading 3.10% higher - a 2.24 point gain - to end the session at 74.44.

Largest decliners

  • Argen-X (EBR:ARGX) was the weakest name on the BEL 20, plunging 7.92% or 64.40 points to close at 748.60.
  • Umicore SA (EBR:UMI) fell 6.66%, a drop of 1.50 points, finishing at 21.02.
  • Aperam SA (AS:APAM) declined 4.23%, losing 1.98 points to end at 44.78.

Across the Brussels Stock Exchange, decliners marginally outnumbered advancers: 45 stocks fell while 42 rose, and 19 issues finished unchanged.

Notable milestone

Shares of Anheuser Busch Inbev SA NV (EBR:ABI) reached five-year highs during the session, closing up 3.10% at 74.44.


Commodities and currency moves

Gold Futures for August delivery fell 3.13%, down $129.73, to settle at $4,019.67 per troy ounce. In energy markets, crude oil for August delivery dropped 3.81%, a decline of $2.79, to $70.42 a barrel. The September Brent contract decreased 3.62%, or $2.78, to trade at $74.02 a barrel.

Currency moves were muted: the EUR/USD pair was essentially unchanged, quoted at 1.13 with a 0.28% notation, and EUR/GBP was unchanged at 0.86.

The US Dollar Index futures were up modestly by 0.22%, trading at 101.39.


Market participants in Brussels closed the session with the BEL 20 lower by 0.72%, driven by losses in key sectors and weighed down by several sizable single-stock declines, while a handful of names delivered outsized gains.

Risks

  • Sector-specific weakness in Healthcare, Basic Materials and Utilities could continue to pressure the BEL 20 - impacting financial performance of companies within those sectors.
  • Downward moves in commodities such as oil and gold may affect companies exposed to commodity price changes, including firms in basic materials and energy-linked sectors.
  • Notable single-stock declines, such as the steep drop in Argen-X and falls in Umicore and Aperam, introduce volatility risk for the broader index performance.

More from Stock Markets

Cerebras CEO Says Investors Misread 2026 Margin Outlook as Stock Plunges Jun 24, 2026 Airbus to Back Inspections of Select A380 Wings After Spar Cracks Identified Jun 24, 2026 UBS boosts targets for AMD and Arm, cites standalone CPU demand but tempers TAM optimism Jun 24, 2026 TD Cowen Names Agios Its Top Biotech Pick on Strength in Thalassemia and Pipeline Progress Jun 24, 2026 Cantor Fitzgerald Initiation Sends Silence Therapeutics Stock Higher Ahead of Pivotal Divesiran Readout Jun 24, 2026